This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Dan DeNeui Named COO Of BioTE Medical

DALLAS, Jan. 24, 2013 /PRNewswire/ -- BioTE Medical founder and President Dr. Gary Donovitz today announced the promotion of Dan DeNeui to COO.    BioTE Medical is a Texas-based company that has played a significant role in the development of subcutaneous testosterone pellet therapy for men and women.  DeNeui had been serving as the company's Vice President-Business Development.   


Commenting on the promotion of DeNeui, Dr. Donovitz said, " Dan DeNeui has been such a critical part of our success at BioTE Medical.   He was been instrumental in the launching of our company several years ago and is a major reason that BioTE is emerging as a national leader in the field of safe and effective testosterone replacement for men and women."  According to Donovitz, DeNeui led an expansion of BioTE Medical to new markets.  Donovitz added, "Because of Dan and our team, the BioTE Method of safe and effective testosterone pellet therapy is now being offered by leading medical professionals in a number of markets in the US.  With the momentum that's been built, BioTE testosterone pellet therapy will be available coast to coast in the next year." 

Dan DeNeui stated, "It's been a privilege to work with Dr. Donovitz, my staff and the medical practitioners who offer the BioTE Method.   It's been very exciting to see our growth over the past 3 years.   It is evident that BioTE is on the verge of some very exciting times ahead. We currently boast the largest patient population receiving the exact same Bio Identical Hormone Replacement Therapy in the US, and that number is growing exponentially each year.  This obviously provides our company with some incredible opportunities."

In a marketplace that is becoming increasingly competitive with testosterone replacement creams, gels and shots, DeNeui said that the BioTE Method is being enthusiastically received by both consumers and physicians.   DeNeui added, "There are numerous products on the market that simply don't work efficiently.  And there are others, such as synthetic testosterone shots, that can present major issues for consumers.  At BioTE Medical, we're driven by excellence.  Bio-identical testosterone pellet therapy is by far the best method for both men and women to safely balance their hormones.   And as trained medical professionals compare other modalities with BioTE Medical's testosterone pellets, we have become the best practices standard." 

Dr. Donovitz praised the quality of physicians and medical practitioners who have joined team of professionals offering the BioTE Method.   Donovitz stated, "We've been able to align ourselves with the best physicians and medical professionals in all of our markets.    Compared to other clinics offering hormone replacement therapy, our physicians are clearly the most knowledgeable, best trained and most successful." 

Both Donovitz and DeNeui cited BioTE Medical's physician training as a point of differentiation.   DeNeui added, "When BioTE Medical partners with a doctor, we start with very complete training for not only the doctor but also their key employees.  And it doesn't stop there.   We're very committed to ongoing dialog and support.  In fact, we have a division of the company that offers marketing support for our partners." 

Regarding the growth of BioTE Medical, both Dr. Donovitz and DeNeui agree that the company is on the verge of significant growth.  Dr. Donovitz added, "We're positioned well for major growth this year and beyond.   Dan's done an exemplary job of building the infrastructure.   The future is, indeed, very bright." 

Interviews Available

Contact: Pete Thomson McQ Media214-257-8484

SOURCE BioTE Medical

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.19 -1.04%
FB $118.08 0.55%
GOOG $695.81 0.50%
TSLA $234.18 0.80%
YHOO $35.97 -0.11%


Chart of I:DJI
DOW 17,651.26 -99.65 -0.56%
S&P 500 2,051.12 -12.25 -0.59%
NASDAQ 4,725.6390 -37.5850 -0.79%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs